Association between platelet reactivity and circulating platelet-derived microvesicles in patients with acute coronary syndrome

Platelets

Volumn 26, Issue 5, 2015, Pages 467-473

  Kafian, Sam ^a   Mobarrez, Fariborz ^a   Wallén, Håkan ^a   Samad, Bassem ^a  

^a DANDERYD HOSPITAL   (Sweden)

Author keywords

Acute coronary syndrome; Clopidogrel; Multiple electrode aggregometry; Platelet derived microvesicles; Platelets

Indexed keywords

BIOLOGICAL MARKER; CD40 LIGAND; CLOPIDOGREL; PADGEM PROTEIN; PHOSPHATIDYLSERINE; ANTITHROMBOCYTIC AGENT;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FLOW CYTOMETRY; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET MICROPARTICLE; PLATELET REACTIVITY; PRIORITY JOURNAL; SMOKING; ST SEGMENT; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; DRUG EFFECTS; MEMBRANE MICROPARTICLE; METABOLISM; MIDDLE AGED; RISK FACTOR; THROMBOCYTE;

PAPAYA MOSAIC VIRUS;

ACUTE CORONARY SYNDROME; AGED; BLOOD PLATELETS; CELL-DERIVED MICROPARTICLES; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RISK FACTORS;

EID: 84931376465     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2014.940304     Document Type: Article

References (32)

1. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32: 2999-3054.
2. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, Costa MA. Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives. J Am Coll Cardiol 2007;49:1505-1516.
3. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schomig A, Kastrati A, von Beckerath N. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009;53:849-856.
4. Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006;27: 1166-1173.
5. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057.
6. Aradi D, Tornyos A, Pinter T, Vorobcsuk A, Konyi A, Falukozi J, Veress G, Magyari B, Horvath IG, Komocsi A. Optimizing P2Yreceptor inhibition in acute coronary syndrome patients based on platelet function testing: Impact of prasugrel and high-dose clopidogrel. J Am Coll Cardiol 2014;63:1061-1070.
7. Janssen PW, Ten Berg JM, Hackeng CM. The use of platelet function testing in PCI and CABG patients. Blood Rev 2014;28: 109-121.
8. Gurbel PA, Rafeedheen R, Tantry US. Personalized antiplatelet therapy. Rev Esp Cardiol (Engl Ed) 2014;67:480-487.
9. Kafian S, Mobarrez F, Kalani M, Wallen H, Samad BA. Comparison of venous and arterial blood sampling for the assessment of platelet aggregation with whole blood impedance aggregometry. Scand J Clin Lab Invest 2011;71:637-640.
10. Sibbing D, Schulz S, Braun S, Morath T, Stegherr J, Mehilli J, Schomig A, von Beckerath N, Kastrati A. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010;8:250-256.
11. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial. JAMA 2011;305:1097-1105.
12. Collet JP, Cayla G, Cuisset T, Elhadad S, Range G, Vicaut E, Montalescot G. Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: Rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel after DES implantation, and (2) treatment interruption versus continuation, 1 year after stenting (ARCTIC) study. Am Heart J 2011;161:5-12e5.
13. Siller-Matula JM, Francesconi M, Dechant C, Jilma B, Maurer G, Delle-Karth G, Gouya G, Ruzicka K, Podczeck-Schweighofer A, Christ G. Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study. Int J Cardiol 2013; 167:2018-2023.
14. Aradi D, Komocsi A, Vorobcsuk A, Rideg O, Tokes-Fuzesi M, Magyarlaki T, Horvath IG, Serebruany VL. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and meta-analysis. Am Heart J 2010;160:543-551.
15. Piccin A, Murphy WG, Smith OP. Circulating microparticles: Pathophysiology and clinical implications. Blood Rev 2007;21: 157-171.
16. Suades R, Padro T, Vilahur G, Badimon L. Circulating and plateletderived microparticles in human blood enhance thrombosis on atherosclerotic plaques. Thromb Haemost 2012;108:1208-1219.
17. Baron M, Boulanger CM, Staels B, Tailleux A. Cell-derived microparticles in atherosclerosis: Biomarkers and targets for pharmacological modulation? J Cell Mol Med 2012;16:1365-1376.
18. Martinez MC, Tual-Chalot S, Leonetti D, Andriantsitohaina R. Microparticles: Targets and tools in cardiovascular disease. Trends Pharmacol Sci 2011;32:659-665.
19. Burger D, Schock S, Thompson CS, Montezano AC, Hakim AM, Touyz RM. Microparticles: Biomarkers and beyond. Clin Sci (Lond) 2013;124:423-441.
20. Toth O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electrode aggregometry: A new device to measure platelet aggregation in whole blood. Thromb Haemost 2006;96:781-788.
21. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013;62:2261-2273.
22. Sibbing D, Byrne RA, Bernlochner I, Kastrati A. High platelet reactivity and clinical outcome-Fact and fiction. Thromb Haemost 2011;106:191-202.
23. Mobarrez F, Antovic J, Egberg N, Hansson M, Jorneskog G, Hultenby K, Wallen H. A multicolor flow cytometric assay for measurement of platelet-derived microparticles. Thromb Res 2010; 125:e110-e116.
24. Kalantzi KI, Dimitriou AA, Goudevenos JA, Tselepis AD. The platelet hyporesponsiveness to clopidogrel in acute coronary syndrome patients treated with 75 mg/day clopidogrel may be overcome within 1 month of treatment. Platelets 2012;23: 121-131.
25. Paniccia R, Antonucci E, Maggini N, Romano E, Gori AM, Marcucci R, Prisco D, Abbate R. Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy. Am J Clin Pathol 2009;131:834-842.
26. Skeppholm M, Mobarrez F, Malmqvist K, Wallen H. Plateletderived microparticles during and after acute coronary syndrome. Thromb Haemost 2012;107:1122-1129.
27. Sinauridze EI, Kireev DA, Popenko NY, Pichugin AV, Panteleev MA, Krymskaya OV, Ataullakhanov FI. Platelet microparticle membranes have 50-to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 2007;97: 425-434.
28. Herring JM, McMichael MA, Smith SA. Microparticles in health and disease. J Vet Intern Med 2013;27:1020-1033.
29. Jung C, Sorensson P, Saleh N, Arheden H, Ryden L, Pernow J. Circulating endothelial and platelet derived microparticles reflect the size of myocardium at risk in patients with ST-elevation myocardial infarction. Atherosclerosis 2012;221:226-231.
30. Guidollet J, Chignier E, Pillot R, Gayet O, MacGregor J, Louisot P. Enhanced expression of P-selectin (CD62P) by endothelial cells seeded onto synthetic arterial prostheses (PET, Dacron) is correlated with leukocyte interactions. J Biomed Mater Res 1999;44: 156-161.
31. Lievens D, Zernecke A, Seijkens T, Soehnlein O, Beckers L, Munnix IC, Wijnands E, Goossens P, van Kruchten R, Thevissen L and others. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood 2010;116:4317-4327.
32. Collet JP, Cuisset T, Range G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff P, Carrie D, Boueri Z, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367:2100-2109.